| BC | Breast cancer |
| ADR(s) | Adverse drug reaction(s) |
| DDI | Drug–drug interaction |
| QOL | Quality of life |
| BSE | Breast self-examination |
| RCT | Randomized controlled trial |
| MTM | Medication therapy management |
| CMM | Comprehensive medication management |
| OHT | Oral hormonal therapy |
| QALYs | Quality-adjusted life years |
| ER | Emergency room |
| DRP | Drug-related problem |
| CSI | Clinically significant interactions |
| CDTM | Collaborative drug therapy management |
| CAIT | Cancer and Aging Interdisciplinary Team |
| CB-PCT | Consultation-Based Palliative Care Team |
| EPR | Electronic patient record |
| AET | Adjuvant endocrine therapy |
| CDK4/6i | Cyclin-dependent kinase 4/6 inhibitor |
| COVID-19 | Corona Virus Disease 2019 |
| HFS | Capecitabine-related hand–foot syndrome |
| AEs | Adverse events |